Purchase this article with an account.
Thomas Ness, Daniel Boehringer, Amelie Pielen, Sonja Heinzelmann; Comparison of the effect of Dexamethasone drug delivery system in macular edema in patients with uveitis or retinal vein occlusion. Invest. Ophthalmol. Vis. Sci. 2013;54(15):5388.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To compare the effect of a dexamethasone drug delivery system (Ozurdex) on macular edema in patients with persistent macular edema due to inflammation or retinal vein occlusion.
Eighty-four patients (35 uveitis/49 retinal vein occlusion) injected with Ozurdex from September 2010 to November 2012 at an academic center were included. Thirty-four eyes were reinjected up to 4 times. Visual acuity, total macular volume, rate of relapses, treatment survival analysis and side effects were evaluated retrospectively .
The primary response rate to Ozurdex (visual acuity and/or reduction of total macular volume) was 100% in uveitis patients and 82% in retinal vein occlusion patients (p<0.01). In both groups, visual acuity improved and total macular volume decreased significantly. After the first and second injection the mean time interval until relapse was 145/143 days in uveitis and 160/160 days in retinal vein occlusion, respectively. It seemed to be longer after the third injection in uveitis (367 days), while it was unchanged in retinal vein occlusion (147 days). The rate of cataract formation and intraocular pressure rise was low in both groups.
After the injection of Ozurdex macular edema in uveitis responded more frequently than macular edema in retinal vein occlusion. In contrast to retinal vein occlusion, in uveitis the effect of the injection seemed to be prolonged after at least three injections. Since there were a low number of complications, Ozurdex is an alternative to treat patients with persistent macular edema in uveitis.
This PDF is available to Subscribers Only